Pages that link to "Q36409878"

The following pages link to Phase I trial of a Lactobacillus crispatus vaginal suppository for prevention of recurrent urinary tract infection in women (Q36409878):

Displaying 22 items.

• Interventions for preventing recurrent urinary tract infection during pregnancy (Q24186322) (← links)
• Probiotics for preventing urinary tract infections in adults and children (Q24186954) (← links)
• Interventions for preventing recurrent urinary tract infection during pregnancy (Q24202838) (← links)
• Interventions for preventing recurrent urinary tract infection during pregnancy (Q24235179) (← links)
• New approaches to making the microenvironment of the female reproductive tract hostile to HIV. (Q30398454) (← links)
• Guide to designing, conducting, publishing and communicating results of clinical studies involving probiotic applications in human participants (Q34165056) (← links)
• Probiotic therapy: immunomodulating approach toward urinary tract infection (Q34214512) (← links)
• The role of lactobacilli and probiotics in maintaining vaginal health (Q34381043) (← links)
• Asymptomatic bacteriuria Escherichia coli are live biotherapeutics for UTI. (Q34535160) (← links)
• Primary and secondary prevention of urinary tract infections (Q34632416) (← links)
• Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection (Q34814831) (← links)
• Probiotic Properties of Lactobacillus crispatus 2,029: Homeostatic Interaction with Cervicovaginal Epithelial Cells and Antagonistic Activity to Genitourinary Pathogens (Q35207445) (← links)
• Effects of Bacterial Vaginosis-Associated Bacteria and Sexual Intercourse on Vaginal Colonization With the Probiotic Lactobacillus crispatus CTV-05 (Q35346663) (← links)
• Evaluation of profertility effect of probiotic Lactobacillus plantarum 2621 in a murine model (Q35742149) (← links)
• Recurrent urinary tract infections in children: Preventive interventions other than prophylactic antibiotics (Q35788472) (← links)
• Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections. (Q36951570) (← links)
• Phase 1 dose-ranging safety trial of Lactobacillus crispatus CTV-05 for the prevention of bacterial vaginosis (Q37377950) (← links)
• Therapeutical use of probiotic formulations in clinical practice. (Q37767505) (← links)
• Probiotics for preventing urinary tract infection in people with neuropathic bladder. (Q40061031) (← links)
• Cytoprotective Effect of Lactobacillus crispatus CTV-05 against Uropathogenic E. coli. (Q54339663) (← links)
• Ureaplasma urealyticum and Mycoplasma hominis Sensitivity to Bacteriocins Produced by Two Lactobacilli Strains (Q84629579) (← links)
• Warding Off Recurrent Yeast and Bacterial Vaginal Infections: Lactoferrin and Lactobacilli (Q92811888) (← links)